Gary W. Pace, Director at Cardiff Oncology, Inc. (CRDF), bought 290,000 shares at $2.45 ($711K) on 2025-07-30, disclosed to the SEC on 2025-07-31.
Open-market purchase of $710k CRDF by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.45 | 15,000 | $37K | 5.2% |
| 2 | $2.45 | 275,000 | $674K | 94.8% |
| Total | $2.45 avg | 290,000 | $711K | 100% |
| Filing → |
| CRDF | BUY | 2024-12-12 | $940K | — | Filing → |
| PCRX | SELL | 2024-03-08 | $4.5M | — | Filing → |
| CRDF | BUY | 2023-12-19 | $41K | — | Filing → |